MedPath

Cutibacterium Acnes in Bone and Joint Infections

Conditions
Prosthesis and Bone Infections
Cutibacterium Acnes
Registration Number
NCT03950063
Lead Sponsor
CHU de Reims
Brief Summary

Prosthetic Joint Infections (PJIs) are increasing with the use of orthopedic devices on an ageing population. Cutibacterium acnes is a commensal organism that plays an important role in the ecosystem healthy human skin, yet this species is also recognized as a pathogen in foreign body infection: endocarditis, prostatitis and specifically in PJIs. C. acnes is able to escape the immune system. This phenomenon could reflect two bacterial behavior: the bacterial internalization by host cells and the biofilm formation.

Detailed Description

The aim of the study is to evaluate specific pathogenicity factors (ability to internalize bone cells and ability to form a biofilm) of bacteria derived from clinical strains of C. acnes isolated from bone infections on orthopedic material.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • bone infection with C. acnes,
  • isolation of the strain,
  • presence of a single species,
  • conservation of a viable strain,
  • patients over 18 years
Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Internalization capacity of C. acnes strainsDay 0

C. acnes strains will be cultured for 5 days in rich medium at 37°C in anaerobic conditions. Then, the bacteria will be co cultured with bone cells (osteoblast) and bacteria will be internalized by the bone cells. After killing bacteria stayed outside of the cells with an antibiotic and lysis of the cells, the number of bacteria internalized will be counted on agar plate.

Biofilm capacity of C. acnes strainsDay 0

C. acnes strains will be cultured for 5 days in rich medium at 37°C in anaerobic conditions. Then, the biofilm biomass will be evaluated by Crystal violet staining. The amount of biofilm will be evaluated by absorbance (optic density by spectrophotometry).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Damien JOLLY

🇫🇷

Reims, France

© Copyright 2025. All Rights Reserved by MedPath